University of Arizona

Phoenix, Arizona
Howard J. Schaeffer Endowed Chair in Pharmaceutical Sciences, University of Arizona
Professor, University of Arizona’s College of Pharmacy
Co-Director, Molecular Therapeutics Program, University of Arizona’s Cancer Center
Associate Director, BIO5 Institute


Dr. Hurley’s current research focuses on the design and development of anti-tumor agents.

Throughout the past 20 years, Dr. Hurley’s laboratory has found seven different groups of compounds that may be useful in the treatment of cancer. The studies have been used in the biopharmaceutical industry to develop several drugs that were evaluated in clinical trials. Quarfloxin, for example – which was discovered and developed by Dr. Hurley – is the first-in-class G-quadruplex-interactive molecule that reached phase II clinical trials.

At the NFCR Center for Targeted Cancer Therapies (2001– 2017), Co-Directors Dr. Hurley and Dr. Daniel Von Hoff worked together on a genetic structure-based approach to drug design. They combine Dr. Hurley’s medicinal chemistry research with Dr. Von Hoff’s clinical oncology program in cancer therapeutics.

The team has identified, designed and synthesized multiple new compounds that selectively kill pancreatic cancer cells with mutations in the cancer-causing K-ras gene—which are present in more than 90% of pancreatic tumors. The leading compounds are being further developed for possible clinical translation.

With Dr. Hurley’s expertise in G-quadruplex-interactive molecules, the team at the Center has also worked on an entirely new approach to treating cancer by developing G-quadruplex drugs that block newly-recognized genetic structures called “super enhancers.” These large clusters of DNA regulatory elements control the expression of a host of genes — including the critical cancer gene c-Myc – and offer a great opportunity for cancer disruption. This new approach may lead to great improved treatments for lung cancer- in particular small-cell type, pancreatic cancer, lymphoma, multiple myeloma, colorectal and other cancers.


Laurence Hurley, Ph.D., was born in Birmingham, England and he received his Bachelor of Pharmacy from Bath University. He then received his Ph.D. from Purdue University and conducted his postdoctoral research at the University of British Columbia. He has served on the faculties at the University of Maryland, the University of Kentucky and the University of Texas at Austin. In 2000, Dr. Hurley joined the University of Arizona (UA) as the Howard J. Schaeffer Chair in Pharmaceutical Sciences and he has served as the Associate Director of the BIO5 Collaborative Research Institute and Co-Director of the Molecular Therapeutics Program at the Arizona Cancer Center as well. While at UA, he has trained more than 40 graduate and post-doctoral students. A prolific author and inventor, Dr. Hurley has published 270 peer-reviewed articles and 25 issued patents or patent applications. He has placed two novel cancer medicines into human clinical trials.

Dr. Hurley is the scientific founder of Cylene Pharmaceuticals, where the Quarfloxin molecule was discovered and developed. He is also the scientific founder and CEO of TetraGene, a biotech company that focuses on targeting secondary DNA structures. He is the founder and CSO of Reglagene, the biotech company focusing on the discovery of small molecule drugs that selectively interact with quadruplexes to regulate gene expression. Additionally, Dr. Hurley has been a consultant to pharmaceutical companies throughout his career.

From 1992 to 2010, Dr. Hurley was a senior editor of the Journal of Medicinal Chemistry and, from 2008 to 2012, he was a member and then chair of the National Cancer Institute’s Scientific Board of Councilors. He is the recipient of various lectureships, including the 2001 Frank Rose Memorial Lecture at the British Association for Cancer Research, the 1999 Prestige Lectureship at Bradford University, the 2007 Mary E. Kapp Lecturer in Chemistry at the Virginia Commonwealth University and the 2012 Hecht Lecturer at the University of Virginia. In 1996, he was awarded a Doctor of Science degree from his alma mater, Bath University.

Dr. Hurley received the 1988 George Hitchings Award in Innovative Methods in Drug Design, the 1989 Volwiler Research Achievement Award from the American Association of Colleges of Pharmacy, the 1992 American Pharmacists Association Research Achievement Award in Medicinal Chemistry, the 1994 National Cancer Institute’s Outstanding Investigator Award, the 1994 American Chemical Society Medicinal Chemistry Award and the 2005 George and Christine Sosnovsky Award in Cancer Therapy from the Royal Society of Chemistry. In 2007, Dr. Hurley was inducted into the American Chemical Society’s Medicinal Chemistry Hall of Fame and was named Innovator of the Year by the University of Arizona. Subsequently, Dr. Hurley received the 2008 American Association of Colleges of Pharmacy’s Paul R. Dawson Biotechnology Award and the 2011 Nucleic Acids Award by the Royal Society for Chemistry.

Related Content

Pancreatic Cancer: Warnings and Wellness

NFCR Chief Medical Officer Shares His Expertise for Improved Pancreatic Cancer Awareness The National Foundation for Cancer Research (NFCR)’s Dr. Brian Leyland-Jones contributed to the popular online platform Eat This, Not That!’s feature in efforts to spread awareness of one of the most deadly and difficult to detect cancers: 11 Warning Signs of Pancreatic Cancer. Dr. Leyland-Jones’ career spans decades, and has led him to become an authority within the pancreatic cancer-fighting community. Dr. Leyland Jones serves as Board Member and Chief Medical Officer for NFCR, offering his extensive expertise to NFCR’s fundraising missions. Boasting over 100 million readers, Eat This, Not That! publishes expert- and research-backed tips on food, nutrition, and health. Dr. Leyland-Jones’ tips on pancreatic cancer awareness help strengthen the deep catalogue of recipes, diet recommendations, and general wellness tips on the popular online platform. Warning Signs Early detection is crucial for early intervention with pancreatic cancer. The disease has an overall five-year survival rate of just 9% and is likely to rise to become the second leading cause of cancer-related deaths in the U.S. by the year 2030. These facts, coupled with pancreatic cancer’s significant reputation as one of the silent killers, showcase the importance of knowing these 11 warning signs: Blood Clots Ascites Jaundice Sudden Weight Loss Upper Abdominal Pain Depression and Anxiety (Before Diagnosis) Nausea and Vomiting Diabetes Pale Feces and Dark Urine Enlarged Gallbladder or Liver Unexplainable Fatigue Outside of these symptoms, Dr. Leyland-Jones emphasizes the importance of keeping up-to-date on your yearly physicals, stating, “It is very difficult to detect early. For yearly physicals, some people also get PET scans and CT scans. However, the progression is so fast, these kinds of scans would need to be done every six months.” With approximately 60,000 new cases per year, pancreatic cancer will continue to be a significant concern. Know these warning signs and keep up with day-to-day wellness and yearly physicals in order to stay on top of your health!   Did you know that November is Pancreatic Cancer Awareness Month? Subscribe to NFCR social media channels to stay up to date on the latest developments in the fight against pancreatic cancer. You can also visit our donation page to join in our fundraising efforts! Additional Reads You May Enjoy: Thunder God Vine: A Powerful Discovery for Pancreatic Cancer Patients 5 Tips for Eating Healthy While Traveling Coping With Cancer—It’s Different for Everyone Receive our monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips and more. Sign up here. 

Thunder God Vine: A Powerful Discovery for Pancreatic Cancer Patients

With a name as powerful as Thunder God Vine comes great responsibility – and National Foundation for Cancer Research (NFCR)-funded researcher Dr. Daniel D. Von Hoff has proven that this medicinal plant is up for the challenge.  Dr. Von Hoff is considered one of the nation’s leading authorities on pancreatic cancer.  He and his team began exploring how thunder god vine — an herb used in China for centuries to treat joint pain, swelling, and fever — could be used for cancer patients. The team was overcome with excitement as they discovered a particular compound in this miracle herb can kill cancer cells and potentially improve clinical outcomes for patients with pancreatic cancer. Pancreatic cancer is the ninth and tenth most commonly diagnosed cancer in women and men, respectively, in the United States. It is the fourth deadliest cancer and is one of the few cancers for which survival has not improved substantially in over 40 years. An estimated 57,600 new cases of pancreatic cancer will be diagnosed in the United States this year, with 47,050 deaths expected to result from the diagnosis. With little to no groundbreaking discoveries or treatment, pancreatic cancer is expected to become the second leading cause of cancer-related deaths in the United States by 2030. The key ingredient of the thunder god vine is called triptolide. Triptolide makes up a molecule called Minnelide, which appears to attack pancreatic cancer cells. It also attacks the tumor’s stroma or outer layer that shields it from the body’s immune system. This allows Minnelide to disrupt ‘super-enhancers,’ strings of DNA that aid the growth and survival of pancreatic cancer cells. The team found that disrupting these super-enhancers attacks the cancer cells and the stroma, which helps accelerate cancer cell death. Thunder god vine is commonly found in China and has been used in traditional Chinese medicine for hundreds of years. The approaches that make up traditional Chinese medicine, including acupuncture, tai chi, and herbal products, have been the subjects of many clinical studies and scientific reviews. Researchers have concluded that traditional Chinese medicine may help improve quality of life and certain pain conditions, and it is becoming more and more prevalent in western medicine practices. Today, for example, thunder god vine is used for rheumatoid arthritis, multiple sclerosis, Crohn’s disease, lupus, psoriasis, fever, amongst other conditions.  This new approach using an old method may provide means for effective treatment options for pancreatic cancer patients, a glimmer of hope that health professionals and patients have long-awaited. To learn more about groundbreaking research undertaken by NFCR-funded researchers, visit our scientist page. Additional Reads You May Enjoy: Controlling the Uncontrollable: HER2 Breast Cancer Propelling the Fight Against Pancreatic Cancer Ancient Wisdom, Modern Cure Stay connected with the cancer community! Receive NFCR’s monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips, and more. Sign up here.

New Treatment with Combined Immunotherapies is Effective for Drug Resistant Metastatic Lung Cancer